<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; biosimilars</title>
	<atom:link href="http://www.tapanray.in/tag/biosimilars/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Unfettered ‘Access To Drug Innovation’ &#8211; An Oxymoron?</title>
		<link>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unfettered-access-to-drug-innovation-an-oxymoron</link>
		<comments>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/#comments</comments>
		<pubDate>Mon, 06 Sep 2021 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[confidence]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[customer. consumer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[off-patent]]></category>
		<category><![CDATA[Oxymoron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[property< India]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[undermining]]></category>
		<category><![CDATA[unfettered]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10582</guid>
		<description><![CDATA[The mass paranoia, as it were, over Covid pandemic has now started fading with drug regulators’ ‘emergency approval’ of several Covid -19 vaccines, and its free of cost access to all, generally in most countries. As the endgame of the pandemic, &#8230; <a href="http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: Why Prescriptions Aren’t Still Enough?</title>
		<link>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-why-prescriptions-arent-still-enough</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/#comments</comments>
		<pubDate>Mon, 14 Sep 2015 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[filgrastim]]></category>
		<category><![CDATA[filgrastim-sndz]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Hatch-Waxman]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[M&M]]></category>
		<category><![CDATA[marketsandmarkets]]></category>
		<category><![CDATA[Neupogen]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[QuantiaMD]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Zarxio]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7055</guid>
		<description><![CDATA[On September 3, 2015, in a Press Release, Novartis announced, “Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Moving Up The Generic Pharma Value Chain</title>
		<link>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=moving-up-the-generic-pharma-value-chain</link>
		<comments>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/#comments</comments>
		<pubDate>Mon, 30 Jun 2014 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[BIPP]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fondaparinux]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GlobaData]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[moving]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Ohm]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[SBIRI]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Valcyte]]></category>
		<category><![CDATA[valsartan]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5565</guid>
		<description><![CDATA[June 2014 underscores a significant development for the generic drug exporters of India. Much-delayed and highly expected launch of generic Diovan (Valsartan) is now on its way, as Ranbaxy has reportedly received US-FDA approval to launch the first generic version of this blood pressure drug &#8230; <a href="http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biologic Medicine: Ushers in a different &#8216;Mega Race&#8217; for inorganic growth</title>
		<link>http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth</link>
		<comments>http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/#comments</comments>
		<pubDate>Mon, 02 May 2011 00:30:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biologicals]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[different]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[inorganic]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mega]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Race]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Ushers]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=265</guid>
		<description><![CDATA[During the last several years the success of biologics compared to conventional small-molecule drugs to meet the unmet needs of patients, is gradually but surely changing the area of focus of pharmaceutical R&#38;D altogether, making the biotech companies interesting targets &#8230; <a href="http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilars: Creating new vistas of opportunities for Indian Bio Pharmaceutical players in the global market.</title>
		<link>http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market</link>
		<comments>http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/#comments</comments>
		<pubDate>Thu, 31 Dec 2009 01:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bio]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[vistas]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=682</guid>
		<description><![CDATA[Biosimilar or follow-on biologic drugs market is fast evolving across the world with varying degree of pace and stages of developments. The global market for Bio-pharmaceuticals was around US$ 120 billion in 2008, as reported by IMS. However, total turnover &#8230; <a href="http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilars –Indian Pharmaceutical Companies are sharpening their focus on fast growing Oncology segment</title>
		<link>http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment</link>
		<comments>http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/#comments</comments>
		<pubDate>Mon, 13 Jul 2009 01:30:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[fast]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[sharpening]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[their]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=836</guid>
		<description><![CDATA[The global market for Bio-pharmaceuticals is estimated to be around US$ 50 billion by the next year. Currently about 25% of New Molecular Entities (NMEs) under development are of biotech origin. Indian pharmaceutical majors like Dr. Reddy’s Laboratories (DRL), Reliance &#8230; <a href="http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
